Panel Discussion: Integrating Emerging Diagnostic Technologies to Enable Faster, More Informed Clinical Development

3:15 pm - Wednesday 22nd July 2026

  • How to integrate emerging diagnostics, including liquid biopsy, with complimentary modalities to generate earlier, higher confidence clinical signals for Clinical Decision
  • What is required to make these technologies decision-grade at scale, including validation, standardization, operational workflow, Clinical application, Global Deployment
  • Where integration most accelerates development, improving patient selection, response monitoring, and resistance insight to deliver more effective therapies faster

Speakers:

Head, Clinical Genomics, Clinical Measurement Sciences
EMD Serono, An affiliate of Merck KGaA, Darmstadt, Germany
Head, Precision Medicine
Astellas Pharma
Head, Strategic Innovation, Precision & Translational Medicine
Takeda
Executive Director, Early Oncology Translational Lead
Pfizer
Assistant Professor & Co-Chair
UC Santa Cruz & NIH Liquid Biopsy Scientific Interest Group